Core Viewpoint - The company reported record revenue of approximately HKD 6.11 billion for the first half of 2025, with innovative and barrier products accounting for about 51% of total revenue, reflecting a nearly 15 percentage point increase year-on-year [1] Group 1: Financial Performance - The company's net profit for the period was approximately HKD 1.17 billion [1] - Excluding the impact of centralized procurement and exchange rates, the company's revenue grew by about 13% year-on-year [1] Group 2: Research and Development - The company invested approximately HKD 1.02 billion in research and development during the period, achieving 38 significant milestone advancements [1] - The company currently has 42 innovative projects in its pipeline [1] Group 3: Strategic Focus Areas - The company has established a differentiated innovation pipeline in key strategic areas such as nuclear medicine for cancer treatment, respiratory and critical care, innovative ophthalmic drugs, and cardiovascular emergency care [1] - The nuclear medicine segment achieved a remarkable revenue growth of nearly 106% year-on-year, generating HKD 420 million [1][2] Group 4: Product Development and Market Expansion - The company’s product, Yttrium-90 microsphere injection, continues to demonstrate strong market potential with rapid growth [1] - The FDA granted early approval for the product Yigan Tai for the treatment of unresectable hepatocellular carcinoma (HCC), marking it as the first and only selective internal radiation therapy product approved for both HCC and colorectal cancer liver metastases [2] - The company’s innovative radiopharmaceutical GPN02006 for diagnosing HCC has shown breakthrough results in clinical research, enhancing its global development prospects [2] Group 5: Other Core Strategic Areas - The company’s innovative product STC3141 for treating sepsis has successfully reached the endpoint of its Phase II clinical trial in China [3] - The company is advancing its global clinical development for STC3141, having received approvals for clinical trials in five countries across three continents [3] - In the respiratory and critical care sectors, the company is launching several innovative products that are expected to enhance revenue growth [4]
远大医药公布2025中期业绩：61.1亿港元收入再创新高，多款创新产品放量尽显发展韧性